Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review

References

• Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844–851.
   PubMed Web of Science ®Google Scholar
• Horani M, Mahmood S, Aslam TM. Macular atrophy of the retinal pigment epithelium in patients with neovascular age-related macular degeneration: what is the link? Part I: a review of disease characterization and morphological associations. Ophthalmol Ther. 2019;8:235–249.
   PubMed Web of Science ®Google Scholar
• Campbell M, Doyle SL. Current perspectives on established and novel therapies for pathological neovascularization in retinal disease. Biochem Pharmacol. 2019;164:321–325.
   PubMed Web of Science ®Google Scholar
• Daniel E, Pan W, Ying GS, et al. Development and course of scars in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2018;125:1037–1046.
   PubMed Web of Science ®Google Scholar
• Velez-Montoya R, Oliver SC, Olson JL, et al. Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention. Retina. 2014;34:423–441.
   PubMed Web of Science ®Google Scholar
• Mehta S. Age-related macular degeneration. Prim Care. 2015;42:377–391.
   PubMed Web of Science ®Google Scholar
• Eells JT. Mitochondrial dysfunction in the aging retina. Biology (Basel). 2019;8:E31.
   PubMed Web of Science ®Google Scholar
• Léveillard T, Philp NJ, Sennlaub F. Is retinal metabolic dysfunction at the center of the pathogenesis of age-related macular degeneration? Int J Mol Sci. 2019;20:E762.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767–777.
   PubMed Web of Science ®Google Scholar
• Schori C, Trachsel C, Grossmann J, et al. A chronic hypoxic response in photoreceptors alters the vitreous proteome in mice. Exp Eye Res. 2019;185:107690.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites. 2017;7:E48.
   PubMed Web of Science ®Google Scholar
• Mullins RF, Russell SR, Anderson DH, et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. Faseb J. 2000;14:835–846.
   PubMed Web of Science ®Google Scholar
• Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99:14682–14687.
   PubMed Web of Science ®Google Scholar
• Wolfensberger TJ. Macular edema - rationale for therapy. Dev Ophthalmol. 2017;58:74–86.
   PubMedGoogle Scholar
• Remky A, Weber A, Arend O, et al. Topical dorzolamide increases pericentral visual function in age-related maculopathy: pilot study findings with short-wavelength automated perimetry. Acta Ophthalmol Scand. 2005;83:154–160.
   PubMedGoogle Scholar
• Makri OE, Tsekouras IK, Plotas P, et al. Cystoid macular edema due to accidental latanoprost overdose after uncomplicated phacoemulsification. Curr Drug Saf. 2018;13:208–210.
   PubMed Web of Science ®Google Scholar
• Thobani A, Fishman GA. The use of carbonic anhydrase inhibitors in the retreatment of cystic macular lesions in retinitis pigmentosa and X-linked retinoschisis. Retina. 2011;31:312–315.
   PubMed Web of Science ®Google Scholar
• Testa F, Di Iorio V, Gallo B, et al. Carbonic anhydrase inhibitors in patients with X-linked retinoschisis: effects on macular morphology and function. Ophthalmic Genet. 2019;40:207–212.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473:2023–2032.
   PubMed Web of Science ®Google Scholar
• Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106:1190–1195.
   PubMed Web of Science ®Google Scholar
• Braithwaite T, Nanji AA, Lindsley K, et al. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014;5:CD007325.
   PubMed Web of Science ®Google Scholar
• Fine SL, Martin DF, Kirkpatrick P. Pegaptanib sodium. Nat Rev Drug Discov. 2005;4:187–188.
   PubMed Web of Science ®Google Scholar
• Narayanan R, Kuppermann BD, Jones C, et al. Ranibizumab. Nat Rev Drug Discov. 2006;5:815–816.
   PubMed Web of Science ®Google Scholar
• Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11:269–270.
   PubMed Web of Science ®Google Scholar
• Newman DK. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond). 2016;30:202–210.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Goa KL. Verteporfin. Drugs Aging. 2000;16:139–146.
   PubMed Web of Science ®Google Scholar
• Kusuzaki K, Matsubara T, Murata H, et al. Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery? J Enzyme Inhib Med Chem. 2017;32:908–916.
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Keating GM. Pegaptanib: in exudative age-related macular degeneration. Drugs. 2005;65:1571–1577.
   PubMed Web of Science ®Google Scholar
• Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993;12:303–324.
   PubMed Web of Science ®Google Scholar
• Pham B, Thomas SM, Lillie E, et al. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open. 2019;9:e022031.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3:CD005139.
   PubMed Web of Science ®Google Scholar
• Dans KC, Freeman SR, Lin T, et al. Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2019;257:741–748.
   PubMed Web of Science ®Google Scholar
• O’Neil BH, Goldberg RM. Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived. Expert Opin Investig Drugs. 2003;12:1939–1949.
   PubMed Web of Science ®Google Scholar
• Marchetti C, Muzii L, Romito A, et al. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 2019;12:1095–1103.
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124–1133.
   PubMed Web of Science ®Google Scholar
• Al-Khersan H, Hussain RM, Ciulla TA, et al. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019 Jul 12:1–13. in press. DOI:10.1080/14656566.2019.1636031
   PubMed Web of Science ®Google Scholar
• Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296–1304.
   PubMed Web of Science ®Google Scholar
• Scaria A. Compositions and methods for treating and preventing macular degeneration. AU2019203413. 2019.
   Google Scholar
• Nishimiya D, Hashimoto R, Sato T, et al. Peptides for treating age-related macular degeneration. TW201840589. 2018.
   Google Scholar
• Hageman GS. Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration. US2018371547. 2018.
   Google Scholar
• Pries W. Combination therapeutic agent for the treatment of macular degeneration. US2018353530. 2018.
   Google Scholar
• Hageman GS, Mullins RF. Diagnostics and therapeutics for macular degeneration-related disorders. US2018335436. 2018.
   Google Scholar
• Washington I. Compositions and methods for treating macular degeneration. USRE47045. 2018.
   Google Scholar
• Lee JH, Lyu JM. 3-N-Sulfated extracellular N-terminal domain variants of chemokine receptor 3 and composition for preventing or treating aged-related macular degeneration comprising the same. KR20180053929. 2018.
   Google Scholar
• McLaughlin J, Koirala A. Compositions and methods for treating age-related macular degeneration. WO2019079718. 2019.
   Google Scholar
• Zhang S, Yan Q, Dong X, et al. Method for preparing highly-pure ranibizumab inclusion body. CN107602699. 2018.
   Google Scholar
• Peters KG, Shalwitz R. Compositions, formulations and methods for treating ocular diseases. GB2549865. 2017.
   Google Scholar
• Rodrigues GA, Mason M, Christie LA, et al. Functional characterization of Abicipar-Pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability. Invest Ophthalmol Vis Sci. 2018;59:5836–5846.
   PubMed Web of Science ®Google Scholar
• Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014;121:1740–1747.
   PubMed Web of Science ®Google Scholar
• Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev. 2017;7:CD000253.
   PubMedGoogle Scholar
• Coney JM. Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema. Int Med Case Rep J. 2019;12:161–169.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018;8:E25.
   PubMed Web of Science ®Google Scholar
• Arechederra RL, Waheed A, Sly WS, et al. Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion. Bioorg Med Chem. 2013;21:1544–1548.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31:345–360.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat. 2000;10:575–600.
   Web of Science ®Google Scholar
• Masini E, Carta F, Scozzafava A, et al. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:705–716.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007–2011. Expert Opin Ther Pat. 2012;22:79–88.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat. 2018;28:713–721.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12:423–431.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat. 2018;28:709–712.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27:963–970.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018). Expert Opin Ther Pat. 2018;28:729–740.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem. 2011;54:1896–1902.
   PubMed Web of Science ®Google Scholar
• Wolfensberger TJ. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol. 1999;97:387–397.
   PubMed Web of Science ®Google Scholar
• Whitcup SM1, Csaky KG, Podgor MJ, et al. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology. 1996;103:1054–1062.
   PubMed Web of Science ®Google Scholar
• Grover S, Fishman GA, Fiscella RG, et al. Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Retina. 1997;17:222–231.
   PubMed Web of Science ®Google Scholar
• Giusti C, Forte R, Vingolo EM, et al. Is acetazolamide effective in the treatment of diabetic macular edema? A pilot study. Int Ophthalmol. 2001;24:79–88.
   PubMedGoogle Scholar
• Meyer KM, Klink T, Ugurel S, et al. Regression of paclitaxel-induced maculopathy with oral acetazolamide. Graefes Arch Clin Exp Ophthalmol. 2012;250:463–464.
   PubMed Web of Science ®Google Scholar
• Genead MA, McAnany JJ, Fishman GA. Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia. Retina. 2012;32:826–833.
   PubMed Web of Science ®Google Scholar
• Liew G, Moore AT, Webster AR, et al. Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2015;56:1531–1536.
   PubMed Web of Science ®Google Scholar
• Huang Q, Chen R, Lin X, et al. Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: a meta-analysis. PLoS One. 2017;12:e0186180.
   PubMed Web of Science ®Google Scholar
• Kim DG, Yoon CK, Kim HW, et al. Effect of topical dorzolamide therapy on cystoid macular edema in hydroxychloroquine retinopathy. Can J Ophthalmol. 2018;53:e103–e107.
   PubMed Web of Science ®Google Scholar
• Piozzi E, Alessi S, Santambrogio S, et al. Carbonic anhydrase inhibitor with topical NSAID therapy to manage cystoid macular edema in a case of gyrate atrophy. Eur J Ophthalmol. 2017;27:e179–e183.
   PubMed Web of Science ®Google Scholar
• Murray CD, Wood D, Allgar V, et al. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye (Lond). 2014;28:1218–1222.
   PubMed Web of Science ®Google Scholar
• Huckfeldt RM, Comander J. Management of cystoid macular edema in retinitis pigmentosa. Semin Ophthalmol. 2017;32:43–51.
   PubMed Web of Science ®Google Scholar
• Rebello G, Ramesar R, Vorster A, et al. Apoptosis-inducing signal sequence mutation in carbonic anhydrase IV identified in patients with the RP17 form of retinitis pigmentosa. Proc Natl Acad Sci U S A. 2004;101:6617–6622.
   PubMed Web of Science ®Google Scholar